# Relates to payments by a pharmacy benefit manager to in-network pharmacies

**Bill ID:** S9570
**Session:** 2024
**Sponsor:** Neil D. Breslin
**Status:** In Senate Committee
**PDF:** [S9570 PDF](https://legislation.nysenate.gov/pdf/bills/2024/S9570)

## Summary

Requires a pharmacy benefit manager to pay an in-network pharmacy at minimum at the national average drug acquisition cost (NADAC) rate, or at the pharmacy acquisition cost rate if greater or there is not a NADAC rate, plus a professional dispensing fee that is at minimum the professional dispensing fee paid under the state medical assistance program.

---

## Full Text

S T A T E  O F  N E W  Y O R K
 ________________________________________________________________________
 
  9570
 
  I N  S E N A T E
 
  May 16, 2024
  ___________
 
 Introduced  by  Sen. BRESLIN -- read twice and ordered printed, and when
  printed to be committed to the Committee on Health
 
 AN ACT to amend the public health law, in relation to payments by  phar-
  macy benefit managers to in-network pharmacies
 
  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:

  Section 1. Subdivision 1 of section 280-a of the public health law  is
 amended by adding two new paragraphs (j) and (k) read as follows:
  (J) "PHARMACY ACQUISITION COST RATE" MEANS THE COST PAID BY AN IN-NET-
 WORK  PHARMACY TO ACQUIRE GENERIC, BRAND NAME DRUGS OR BIOLOGIC PRODUCTS
 PURSUANT TO COST INVOICES FROM A MANUFACTURER OR A WHOLESALER.
  (K) "NATIONAL AVERAGE DRUG ACQUISITION COST" MEANS THE MONTHLY  SURVEY
 OF  RETAIL  PHARMACIES CONDUCTED BY THE FEDERAL CENTERS FOR MEDICARE AND
 MEDICAID SERVICES (CMS) TO DETERMINE AVERAGE ACQUISITION COST FOR  MEDI-
 CAID COVERED OUTPATIENT DRUGS.
  ยง  2.  Subdivision  3  of  section  280-a of the public health law, as
 amended by chapter 128 of the laws  of  2022,  is  amended  to  read  as
 follows:
  3. Prescriptions. (A) A pharmacy benefit manager may not substitute or
 cause  the substituting of one prescription drug for another in dispens-
 ing a prescription, or alter or cause the altering of  the  terms  of  a
 prescription, except with the approval of the prescriber or as explicit-
 ly required or permitted by law, including regulations of the department
 of  financial  services  or the department of health. The superintendent
 and commissioner, in coordination with each  other,  are  authorized  to
 promulgate  regulations  to  determine when substitution of prescription
 drugs may be required or permitted.
  (B) TO THE EXTENT PERMITTED UNDER  FEDERAL  LAW,  A  PHARMACY  BENEFIT
 MANAGER  SHALL  PAY  AN  IN-NETWORK  PHARMACY AT MINIMUM AT THE NATIONAL
 AVERAGE DRUG ACQUISITION COST (NADAC) RATE OR AT THE  PHARMACY  ACQUISI-
 TION  COST  RATE IF GREATER OR THERE IS NOT A NADAC RATE, PLUS A PROFES-
 SIONAL DISPENSING FEE THAT IS AT MINIMUM THE  PROFESSIONAL  DISPENSING
 FEE  PAID  UNDER  THE  STATE MEDICAL ASSISTANCE PROGRAM.  FOR BRAND NAME
 MEDICATIONS AND BIOLOGIC PRODUCTS THAT REQUIRE SPECIAL PACKAGING,  SHIP-
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
  [ ] is old law to be omitted.
  LBD15487-03-4
 S. 9570  2
 
 PING  OR OTHER COSTS TO  BE INCURRED BY THE  PHARMACY FOR THE DISPENSING
 PROCESS THAT IS GREATER THAN THE PROFESSIONAL DISPENSING FEE PAID BY THE
 STATE MEDICAL ASSISTANCE PROGRAM, IN-NETWORK PHARMACIES SHALL BE PAID  A
 PROFESSIONAL  DISPENSING  FEE  FOR THESE COSTS TO ENSURE AN IN-NETWORK
 PHARMACY IS NOT PAID LESS THAN ITS COST TO ACQUIRE AND DISPENSE  MEDICA-
 TIONS.
  ยง 3. The opening paragraph of subdivision 4 of section  280-a  of  the
 public  health  law,  as  added  by  chapter 828 of the laws of 2021, is
 amended to read as follows:
  A pharmacy benefit manager shall, with respect to contracts between  a
 pharmacy  benefit  manager  and a pharmacy or, alternatively, a pharmacy
 benefit manager and a pharmacy's contracting agent, such as  a  pharmacy
 services  administrative  organization,  include a reasonable process to
 appeal, investigate and resolve disputes regarding multi-source generic,
 BRAND NAME AND BIOLOGIC PRODUCT drug pricing. The appeals process  shall
 include the following provisions:
  ยง 4. This act shall take effect immediately.